NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, June 18, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th ...

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) on behalf of GeneDx stockholders. Our investigation concerns whether GeneDx has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 5, 2025, Grizzly Research ("Grizzly") published a report e ...

行业转型与增长动力 - 医疗服务业正经历技术革新推动的转型 包括远程治疗需求增长 数字医疗(如远程医疗和AI分析)加速发展 这些工具提升诊断效率 优化运营并改善治疗效果[1] - 全球医疗分析市场规模2024年达531亿美元 预计2025-2034年复合年增长率214% 相关企业如CVS Health、BrightSpring和GeneDx将受益[2] - 行业从按量付费转向价值导向模式 医疗旅游复苏进一步推动增长 催生对外部专业服务提供商的需求[3] 三大未来趋势 - **数字化革命**: 美国数字健康市场2024-2028年复合年增长率92% 全球医疗大数据市场规模将从2024年780亿增至2035年5400亿美元 年复合增长率192% AI技术使治疗成本降低50% 患者疗效提升超50%[4] - **医护人员短缺**: COVID-19后医护人员流失加剧 全球到2030年预计短缺990万医生/护士/助产士 美国医院劳动力成本较疫情前每出院病例增长156%[5] - **护理市场复苏**: 护士麻醉师/助产士/执业护士岗位2023-2033年需求将增长40% 年均新增319万个职位 远程监测技术扩展护理服务范围[6] 行业表现与估值 - 医疗服务业Zacks行业排名第67位(前27%) 历史数据显示排名前50%行业表现优于后50%超2倍[7][8] - 行业过去一年股价整体下跌134% 表现逊于医疗板块(跌12%)和标普500指数(涨106%)[10] - 当前行业前瞻市盈率146倍 低于标普500(219倍)和医疗板块(193倍) 五年估值区间为134-201倍[13] 重点公司推荐 - **GeneDx(WGS)**: 专注罕见病基因检测 开发AI驱动的测序分析平台 2025年预期盈利增长336% 收入预计增长225% 评级为强力买入[19][20] - **CVS Health(CVS)**: 整合式药房服务商 2025/2026年盈利增速预计126%/143% 长期盈利年增114% 当前评级买入[22][23] - **BrightSpring(BTSG)**: 社区医疗服务平台 80%分支机构获4星以上评级 2025年预期盈利增长821% 收入预计增长91% 评级买入[26][27]

NEWTOWN, Pa., June 13, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving GeneDx Holdings Corp. ("GeneDx") (NASDAQ: WGS), resulting from allegations of providing potentially misleading business information to the investing public.If you have information that could assist in the GeneDx investigation, or if you are a GeneDx investor who suffered a loss and would like to learn more, you can provide your information HERE.You can also contact ...

LOS ANGELES, June 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. GeneDx is the subject of a report published by Grizzly Research on February 5, ...

GeneDx (WGS) FY Conference June 09, 2025 04:00 PM ET Speaker0 afternoon, everyone. My name is Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. And I have the pleasure of welcoming Kathryn Stuhlen and Kevin Feeley, CEO and President and CFO of GeneDx. Kathryn, Kevin, thank you. Speaker1 Thank you so much for having Thank you. Speaker0 Really appreciate you guys being here. Maybe if we just kind of start off for the benefit of everybody, just give us an overview of the business today a ...

GeneDx (WGS) 2025 Conference June 04, 2025 09:55 AM ET Speaker0 Good. Good morning. I'm Tycho Peterson from the Life Science Tools Diagnostics team. It's my pleasure to introduce our next company this morning, GeneDx. Before we jump into Q and A, going turn it over to Katherine to introduce some media. Speaker1 Wonderful. Well, thank you so much, Tycho. Thank you to the entire Jefferies team. Coming out of another busy ASCO news cycle, I'm happy to turn everyone's attention to another really important area ...

GeneDx Holdings Corp. (WGS) closed the last trading session at $70.02, gaining 4.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $92.86 indicates a 32.6% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $15.09. While the lowest estimate of $78 indicates an 11.4% increase from the current price level, the most optimistic ana ...

SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and retirement accounts like IRAs, and can be bought/sold in the next 72 hours. The stocks mentioned may already be part of the Prudent Biotech, Prudent Healthcare, or Prudent Small Cap model portfolios. As always, kindly do your due diligence. Small caps and biotechs carry a higher risk of losses than the broader market. Opinions can change with time and additional data, with no obligation to update. Companies mentioned he ...